A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Trial to Evaluate the Safety and Efficacy of Delamanid (OPC-67683) Administered Orally as 200 mg Total Daily Dose for Six Months in Patients With Pulmonary Sputum Culture-positive, Multidrug-resistant Tuberculosis

The purpose of this trial is to determine whether delamanid is effective in the treatment of
multidrug-resistant tuberculosis (MDR TB) in combination with other MDR TB medications during
6 months of treatment.

本临床试验旨在评估德拉马尼（delamanid）联合其他耐多药结核病（multidrug-resistant tuberculosis, MDR-TB）治疗药物，在6个月疗程中用于耐多药结核病治疗的有效性。